Literature DB >> 6120766

Microtubule stabilization by taxol inhibits initiation of DNA synthesis by thrombin and by epidermal growth factor.

K L Crossin, D H Carney.   

Abstract

Several observations have suggested that microtubule depolymerization might act as a regulator of cell proliferation. To determine whether microtubule depolymerization is required for growth-factor-induced initiation of DNA synthesis, we treated serum-free cultures of mouse embryo cells with taxol to stabilize their microtubules and measured the initiation of DNA synthesis by thrombin and epidermal growth factor (EGF). Pretreatment of quiescent cultures of mouse embryo cells with 10 microgram/ml taxol inhibited up to 60% of the thrombin-stimulated and 47% of the EGF-stimulated DNA synthesis. This inhibition was dose-dependent for taxol concentrations from 0.3 to 20 microgram/ml. Control experiments showed that taxol did not simply affect uptake of nucleotides, glucose or amino acids, nor did it nonspecifically affect protein synthesis, cell morphology or cell viability. Taxol did not affect binding and internalization of 125I-thrombin or 125I-EGF indicating that the drug does not alter receptor number, affinity or distribution after growth factor binding. Taxol also did not affect the proteolytic activity of thrombin. Thus it appears that the inhibitory effects of taxol are mediated by a direct effect of taxol on microtubules. To determine at what point microtubule stabilization was interrupting the initiation signal, we added taxol at various times after addition of thrombin or EGF. Taxol addition during the first 8 hr after growth factor addition inhibited initiation, but after 8 hr had little if any effect. These results confirm that taxol was not nonspecifically affecting transport or metabolism required for DNA synthesis and indicate that thrombin and EGF may initiate cell proliferation through a gradual microtubule depolymerization or rearrangement that is necessary to commit cells to a replicative cycle.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6120766     DOI: 10.1016/0092-8674(81)90417-7

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  23 in total

Review 1.  Paclitaxel chemotherapy for the treatment of gastric cancer.

Authors:  Junichi Sakamoto; Takanori Matsui; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2009-06-27       Impact factor: 7.370

2.  Cytostatic and apoptotic effects of paclitaxel in human ovarian tumors.

Authors:  N J Millenbaugh; Y Gan; J L Au
Journal:  Pharm Res       Date:  1998-01       Impact factor: 4.200

3.  Proteome analysis of differential protein expression in cervical cancer cells after paclitaxel treatment.

Authors:  Eun-Kyoung Yim; Jun-Sang Bae; Seung-Bak Lee; Keun-Ho Lee; Chan-Joo Kim; Sung-Eun Namkoong; Soo-Jong Um; Jong-Sup Park
Journal:  Cancer Res Treat       Date:  2004-12-31       Impact factor: 4.679

4.  A radiolabeled monoclonal antibody binding assay for cytoskeletal tubulin in cultured cells.

Authors:  R L Ball; D H Carney; T Albrecht; D J Asai; W C Thompson
Journal:  J Cell Biol       Date:  1986-09       Impact factor: 10.539

5.  Differential effect of taxol in rat primary and metastatic prostate tumors: site-dependent pharmacodynamics.

Authors:  W C Yen; M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1996-09       Impact factor: 4.200

6.  Maitake beta-glucan promotes recovery of leukocytes and myeloid cell function in peripheral blood from paclitaxel hematotoxicity.

Authors:  Hong Lin; Elisa de Stanchina; Xi Kathy Zhou; Feng Hong; Andrew Seidman; Monica Fornier; Wei-Lie Xiao; Edward J Kennelly; Kathleen Wesa; Barrie R Cassileth; Susanna Cunningham-Rundles
Journal:  Cancer Immunol Immunother       Date:  2010-02-06       Impact factor: 6.968

7.  Regulation of tubulin and actin mRNA production in rat brain: expression of a new beta-tubulin mRNA with development.

Authors:  J F Bond; S R Farmer
Journal:  Mol Cell Biol       Date:  1983-08       Impact factor: 4.272

8.  Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine.

Authors:  E K Rowinsky; M J Citardi; D A Noe; R C Donehower
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

9.  Role of Plk2 (Snk) in mouse development and cell proliferation.

Authors:  Sheng Ma; Jean Charron; Raymond L Erikson
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

10.  Imbalance of total cellular nucleotide pools and mechanism of the colchicine-induced cell activation.

Authors:  I N Chou; J Zeiger; E Rapaport
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.